WO1998024432A3 - Use of indolinone compounds as modulators of protein kinases - Google Patents

Use of indolinone compounds as modulators of protein kinases Download PDF

Info

Publication number
WO1998024432A3
WO1998024432A3 PCT/US1997/022210 US9722210W WO9824432A3 WO 1998024432 A3 WO1998024432 A3 WO 1998024432A3 US 9722210 W US9722210 W US 9722210W WO 9824432 A3 WO9824432 A3 WO 9824432A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
protein kinases
indolinone compounds
indolinone
compounds
Prior art date
Application number
PCT/US1997/022210
Other languages
French (fr)
Other versions
WO1998024432A2 (en
Inventor
Gerald Mcmahon
Peng Cho Tang
Li Sun
Ngoc My Tran
Original Assignee
Sugen Inc
Gerald Mcmahon
Peng Cho Tang
Li Sun
Ngoc My Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Gerald Mcmahon, Peng Cho Tang, Li Sun, Ngoc My Tran filed Critical Sugen Inc
Priority to AU76226/98A priority Critical patent/AU7622698A/en
Publication of WO1998024432A2 publication Critical patent/WO1998024432A2/en
Publication of WO1998024432A3 publication Critical patent/WO1998024432A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
PCT/US1997/022210 1996-12-05 1997-12-02 Use of indolinone compounds as modulators of protein kinases WO1998024432A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76226/98A AU7622698A (en) 1996-12-05 1997-12-02 Use of indolinone compounds as modulators of protein kinases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3158796P 1996-12-05 1996-12-05
US60/031,587 1996-12-05
US4571697P 1997-05-06 1997-05-06
US60/045,716 1997-05-06

Publications (2)

Publication Number Publication Date
WO1998024432A2 WO1998024432A2 (en) 1998-06-11
WO1998024432A3 true WO1998024432A3 (en) 1998-08-13

Family

ID=26707416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022210 WO1998024432A2 (en) 1996-12-05 1997-12-02 Use of indolinone compounds as modulators of protein kinases

Country Status (2)

Country Link
AU (1) AU7622698A (en)
WO (1) WO1998024432A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19802377A1 (en) * 1998-01-22 1999-08-19 Max Planck Gesellschaft Use of inhibitors for the treatment of RTK-over-functional disorders, especially of cancer
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
BR9910792A (en) 1998-05-29 2002-01-29 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2002532503A (en) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー 4,5-Pyrazinooxindole as a protein kinase inhibitor
BR9916327A (en) 1998-12-17 2001-09-18 Hoffmann La Roche 4-alkenyl (and alkynyl) oxindols as inhibitors of cyclin-dependent kinases, in particular, cdk2
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
JP2002540096A (en) * 1999-03-24 2002-11-26 スージェン・インコーポレーテッド Indolinone compounds as kinase inhibitors
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
DE10237423A1 (en) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
EP1615928A1 (en) 2003-04-10 2006-01-18 F.Hoffmann-La Roche Ag Pyrimido compounds

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
EP0252713A1 (en) * 1986-07-10 1988-01-13 Pfizer Inc. Indolinone derivatives
WO1991013055A2 (en) * 1990-02-28 1991-09-05 Farmitalia Carlo Erba S.R.L. New aryl- and heteroarylethenylene derivatives and process for their preparation
WO1993001182A1 (en) * 1991-07-12 1993-01-21 Farmitalia Carlo Erba Srl Methylen-oxindole derivatives and process for their preparation
WO1995001349A1 (en) * 1993-07-01 1995-01-12 Pharmacia S.P.A. Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
WO1995017181A1 (en) * 1993-12-22 1995-06-29 Pharmacia S.P.A. Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
WO1996022976A1 (en) * 1995-01-26 1996-08-01 Pharmacia S.P.A. Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
WO1996032380A1 (en) * 1995-04-07 1996-10-17 Pharmacia & Upjohn S.P.A. Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
EP0252713A1 (en) * 1986-07-10 1988-01-13 Pfizer Inc. Indolinone derivatives
WO1991013055A2 (en) * 1990-02-28 1991-09-05 Farmitalia Carlo Erba S.R.L. New aryl- and heteroarylethenylene derivatives and process for their preparation
WO1993001182A1 (en) * 1991-07-12 1993-01-21 Farmitalia Carlo Erba Srl Methylen-oxindole derivatives and process for their preparation
WO1995001349A1 (en) * 1993-07-01 1995-01-12 Pharmacia S.P.A. Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
WO1995017181A1 (en) * 1993-12-22 1995-06-29 Pharmacia S.P.A. Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
WO1996022976A1 (en) * 1995-01-26 1996-08-01 Pharmacia S.P.A. Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
WO1996032380A1 (en) * 1995-04-07 1996-10-17 Pharmacia & Upjohn S.P.A. Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M. MOHAMMADI: "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors", SCIENCE, vol. 276, no. 5314, May 1997 (1997-05-01), pages 955 - 960, XP002065235 *
US 08/702,322 1996 *
US 485,323, 1995 *

Also Published As

Publication number Publication date
AU7622698A (en) 1998-06-29
WO1998024432A2 (en) 1998-06-11

Similar Documents

Publication Publication Date Title
WO1998024432A3 (en) Use of indolinone compounds as modulators of protein kinases
MX9606401A (en) Indolinone compounds for the treatment of disease.
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
ATE292623T1 (en) 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ATIVITY
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
AU9158498A (en) Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
EP2280003A3 (en) Process for preparing receptor-type kinase modulators
BG102738A (en) Inhibitors of farnesyl-protein transferase
MX9801093A (en) C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen.
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
DK1255536T3 (en) Indolinone derivatives for modulation of c-kit tyrosine protein kinase
AU8760798A (en) Irreversible inhibitors of tyrosine kinases
CA2262776A1 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
EP1488792A3 (en) Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
WO2002018342A3 (en) Novel autoinducer molecules and uses therefor
NO20010389L (en) Modulation of multiple line kinase proteins
WO1999050440A3 (en) Method to identify modulators of survivin - tubulin interaction
WO1996040113A3 (en) Phosphatase inhibitors
WO2001064741A3 (en) Methods for selectively modulating survivin apoptosis pathways
AU3066697A (en) 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and the ir use as protein kinase c (=pkc) modulators
WO1998055507A3 (en) Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and kinase domain
PT1082415E (en) Methods useful for modulation of angiogenesis using tyrosine kinase src

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase